This 12-week, double-blind, placebo-controlled, multicenter study evaluated the efficacy and safety of budesonide 400 microg administered once daily via Turbuhaler in adults previously treated with at least twice-daily dosing of inhaled corticosteroids. Pulmonary function (FEV1, PEF, FVC, FEF(25-75%)), asthma symptom scores, quality of life, and breakthrough medication use were significantly (p < 0.05) different in patients receiving once-daily budesonide Turbuhaler compared to placebo, and significantly (p < 0.001) more patients receiving placebo discontinued the study. Adverse events were similar between study groups. Once-daily administration of budesonide Turbuhaler was safe and efficacious in patients previously treated with inhaled corticosteroids.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1081/jas-120000808 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
An evaluation of Asthma control using the Asthma control test in patients at the University Hospital, Agadir, Morocco.
Niger Med J
January 2025
Health Sciences Research and Innovation Laboratory Medical School of Medicine & Pharmacy of Agadir, Ibn Zohr University, Agadir-Morocco.
Background: Asthma is a common chronic disease, and asthma control is the major therapeutic objective, thus ensuring a good health-related quality of life. This study aimed to evaluate the level of asthma control in a sample of asthmatic patients followed in allergology consultation during our training using the asthma control test (ACT) and its correlation with other parameters.
Methodology: This is a cross-sectional study of 66 asthmatic patients who were followed in pulmonology consultation at Agadir University Hospital after completing the asthma control test questionnaire over 6 months (June to December 2021).
Background: Chronic obstructive pulmonary disease (COPD) patients commonly exhibit significant morbidity and experience a diminished quality of life. Since there has been no prior research on pneumonia in our study population, we carried out this study to learn more about the situation.
Methods: A retrospective analysis of 912 COPD patients with CAP who were receiving ICS treatment at the DHQ Hospital in Muzaffargarh, Punjab, Pakistan was conducted.
Comparative analysis of ambient, in-home, and personal exposures reveals associations between breathing zone pollutant levels and asthma exacerbations in high-risk children.
Respir Res
January 2025
Center for Genes, Environment, and Health, National Jewish Health, Denver, CO, USA.
Background: Air pollution is associated with poor asthma outcomes in children. However, most studies focus on ambient or indoor monitor pollution levels. Few studies evaluate breathing zone exposures, which may be more consequential for asthma outcomes.
View Article and Find Full Text PDFEffect of azithromycin combined with fluticasone propionate aerosol inhalation on immune function in children with chronic cough caused by Mycoplasma pneumoniae infection.
Eur J Pediatr
January 2025
Department of Pediatrics, Ganzhou People's Hospital, No. 16 Meiguan Avenue, Zhanggong District, Ganzhou, 341000, Jiangxi Province, China.
Unlabelled: This research aimed to describe the effect of azithromycin combined with fluticasone propionate aerosol inhalation on immune function in children with chronic cough caused by Mycoplasma pneumoniae (MP) infection. This study was a retrospective analysis in which 110 children with chronic cough caused by MP infection were divided into two groups based on different treatment methods: 58 cases in the control group treated with azithromycin dry suspension and 52 cases in the intervention group treated with azithromycin dry suspension and fluticasone propionate inhalation aerosol. Lung function, inflammatory factors, immune indicators, laboratory-related indicators, adverse reactions, and therapeutic effects were compared between the two groups.
View Article and Find Full Text PDFBackground: In patients with asthma, bronchoconstriction and airway inflammation both contribute to airway narrowing and airflow limitations, which lead to symptoms and exacerbations. Short-acting beta 2-agonist (SABA)-only rescue therapy addresses only bronchoconstriction and is associated with increased morbidity and mortality. Current asthma management guidelines recommend concomitant treatment of symptoms and inflammation with a fast-acting bronchodilator and inhaled corticosteroid (ICS) as rescue therapy for patients 12 years of age.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!